Vivani Medical, Inc. has reported a net loss of $26.6 million for the fiscal year ending December 31, 2025, an increase from the $23.5 million loss recorded in the previous year. The company's total revenue remains at zero, as it is still in the clinical development stage with no products approved for commercial sale. Operating expenses rose to $27.5 million, up from $24.6 million in 2024, primarily driven by increased research and development costs associated with clinical trials and product development efforts. The company has accumulated a deficit of $148.5 million as of the end of 2025.
Vivani's strategic focus has shifted towards its obesity treatment portfolio, particularly the development of its lead product candidate, NPM-139, a six-month GLP-1 (semaglutide) implant. The company announced positive preclinical results showing approximately 20% weight loss in rats after a single administration of NPM-139, which is expected to enter clinical trials in mid-2026. Additionally, the company has completed its first-in-human clinical trial, LIBERATE-1, for another candidate, NPM-115 (exenatide implant), which demonstrated a positive safety and tolerability profile.
Operationally, Vivani has made significant advancements, including the successful completion of the LIBERATE-1 trial and the lifting of a clinical hold by the FDA for its NPM-119 candidate. The company has also expanded its collaboration with Okava Pharmaceuticals for the development of OKV-119, a GLP-1 implant for companion animals, which has the potential to generate additional revenue streams. As of December 31, 2025, Vivani employed 42 individuals, reflecting its commitment to expanding its workforce to support ongoing and future projects.
Looking ahead, Vivani anticipates the need for substantial additional financing to support its clinical development and commercialization efforts. The company has entered into various financing agreements, including a registered direct offering that generated approximately $9.7 million in gross proceeds. However, the company acknowledges the uncertainty surrounding its ability to raise sufficient capital on favorable terms, which could impact its operational plans and timelines. The management remains focused on advancing its product candidates through clinical trials while exploring strategic partnerships to enhance its market position.
About Vivani Medical, Inc.
Vivani Medical, Inc. is a biopharmaceutical company developing proprietary NanoPortal subdermal drug implants for long-acting delivery of medicines targeting chronic diseases like obesity and type 2 diabetes. Its platform aims to improve medication adherence and tolerability through miniaturized, controlled-release implants, primarily using GLP-1 therapeutics. The company focuses on clinical-stage programs, strategic collaborations, and intellectual property to revolutionize chronic disease treatment.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.